瑞康医药(002589) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,073,027,669.16, a decrease of 49.36% compared to ¥4,093,497,042.67 in the same period last year[5] - The net profit attributable to shareholders was ¥21,159,565.23, down 50.49% from ¥42,736,596.17 year-on-year[5] - The net profit after deducting non-recurring gains and losses was -¥4,256,424.09, representing a decline of 111.08% compared to ¥38,429,500.10 in the previous year[5] - Basic earnings per share were ¥0.014, down 50.00% from ¥0.028 year-on-year[5] - Net profit for Q1 2023 was CNY 32,936,581.69, compared to CNY 146,001,703.08 in the same period last year, indicating a decrease of 77.5%[22] - The net profit for Q1 2023 was CNY 29,983,448.04, a decrease of 69.6% compared to CNY 98,579,158.25 in the same period last year[23] Cash Flow - The net cash flow from operating activities decreased by 42.36% to ¥75,590,663.40 from ¥131,152,117.17 in the same period last year[5] - Cash inflow from operating activities totaled CNY 2,428,371,185.81, a decrease of 51% from CNY 4,954,931,079.23 in the previous year[25] - The net cash flow from operating activities was CNY 75,590,663.40, down 42.5% from CNY 131,152,117.17 in Q1 2022[25] - Cash flow from investing activities showed a net inflow of CNY 247,712,308.90, compared to a net outflow of CNY 275,361,878.78 in the same period last year[26] - Cash flow from financing activities resulted in a net inflow of CNY 57,982,031.64, an increase from CNY 31,077,571.00 in Q1 2022[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥19,189,860,338.12, an increase of 4.68% from ¥18,331,074,646.82 at the end of the previous year[5] - Total current assets increased to CNY 13,947,004,834.98 from CNY 12,819,555,974.53, representing an increase of 8.8%[20] - Total non-current assets decreased to CNY 5,242,855,503.14 from CNY 5,511,518,672.29, reflecting a decline of 4.9%[20] - Total liabilities increased to CNY 13,399,986,928.74 from CNY 12,579,267,518.31, marking an increase of 6.5%[20] - Total equity increased to CNY 5,789,873,409.38 from CNY 5,751,807,128.51, showing a growth of 0.7%[20] Operational Costs - Total operating costs for Q1 2023 were CNY 2,081,916,966.47, down from CNY 3,955,744,878.12, reflecting a reduction of 47.5%[22] - Cash received from sales and services decreased by 51.65% to 224.28 million compared to the same period last year[13] - Cash paid for purchasing goods and services decreased by 42.26% to 211.71 million, reflecting a reduction in sales revenue[13] - Cash paid to employees decreased by 57.17% to 7.63 million, indicating a significant reduction in workforce-related expenses[13] - Cash paid for taxes decreased by 78.53% to 3.86 million, attributed to lower tax obligations compared to the previous year[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 100,246[15] - The top shareholder, Zhang Renrong, holds 14.39% of shares, amounting to 216.50 million shares, with a significant portion pledged[15] Miscellaneous - The company reported a significant increase in investment income of 1,837,627.59% to ¥5,328.83 due to the divestiture of a subsidiary[11] - Short-term borrowings increased by 42.77% to ¥548,213.68 from ¥383,983.47 at the beginning of the year[10] - The company’s research and development expenses decreased by 33.46% to ¥284.67 from ¥427.85 in the previous year[11] - The company’s total liabilities decreased by 62.95% in long-term borrowings to ¥2,490.00 from ¥6,720.00 due to repayment[10] - The company did not conduct an audit for the Q1 2023 report[27] - The report was released on April 29, 2023[28]